Clinical Trials Logo

Clinical Trial Summary

DNA methylation is one of the important ways of protein post-translational modification.Pituitary adenoma (PA) is a benign neuroendocrine tumor that originates from adenohypophysial 45 cells, and accounts for 10%-20% of all primary intracranial tumors. However some PAs can present with high invasiveness and irregular growth, which tend to compresses the optic chiasm and third ventricle, encase the internal carotid artery, and affect hormone secretion from the pituitary gland and hypothalamus. In this study we focus on the mechanism of DNA methylation on the invasiveness of pituitary tumors.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05634655
Study type Observational
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Wu Qun
Phone 13605810393
Email 2192010@zju.edu.cn
Status Recruiting
Phase
Start date January 1, 2022
Completion date January 1, 2025

See also
  Status Clinical Trial Phase
Completed NCT01903967 - Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH) N/A
Completed NCT01689727 - Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors Phase 2
Completed NCT01322945 - Barrow Nasal Inventory Survey N/A
Completed NCT00565903 - Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Completed NCT01794793 - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies Phase 4
Completed NCT00462475 - Effect of 5 Years of GH Replacement on Atherosclerosis Phase 4